“In 2016, a blockbuster drug called Humira was poised to become a lot less valuable,” Rebecca Robbins writes over at The New York Times. “The key patent on the best-selling anti-inflammatory medication, used to treat conditions like arthritis, was expiring at the end of the year. Regulators had blessed a rival version of the drug, […]